J
J. Baselga
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 169
Citations - 3618
J. Baselga is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 34, co-authored 169 publications receiving 3411 citations.
Papers
More filters
Journal ArticleDOI
TACE is required for the activation of the EGFR by TGF-α in tumors
TL;DR: It is shown that when its proteolytic shedding is prevented, the transmembrane form of the transforming growth factor‐α (proTGF‐α) interacts with, but does not activate, the EGFR, indicating a crucial role of TACE in tumorigenesis.
Journal ArticleDOI
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cristina Cruz,Marta Castroviejo-Bermejo,Sara Gutiérrez-Enríquez,Alba Llop-Guevara,Yasir H. Ibrahim,Albert Gris-Oliver,Sandra Bonache,Beatriz Morancho,Alejandra Bruna,Oscar M. Rueda,Zhongwu Lai,Urszula M. Polanska,Gemma N Jones,Petra Kristel,L. de Bustos,Mario Guzmán,Olga Rodriguez,Judit Grueso,Gemma Montalban,Ginevra Caratu,Francesco M. Mancuso,Roberta Fasani,J. Jimenez,William J. Howat,Brian Dougherty,Ana Vivancos,Paolo Nuciforo,Xavier Serres-Créixams,Isabel T. Rubio,Ana Oaknin,Elaine Cadogan,J.C. Barrett,Carlos Caldas,Carlos Caldas,J. Baselga,Cristina Saura,J. Cortés,Joaquín Arribas,Jos Jonkers,Orland Diez,Mark J. O'Connor,Judith Balmaña,Violeta Serra +42 more
TL;DR: In this paper, the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi were investigated.
Journal ArticleDOI
A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy
Joyce O'Shaughnessy,K. L. Blackwell,Harold J. Burstein,Anna Maria Storniolo,George W. Sledge,J. Baselga,Maria Koehler,S. Laabs,A. Florance,D. Roychowdhury +9 more
TL;DR: The primary endpoint was PFS, and secondary endpoints were clinical benefit rate (CBR) at 24 wks, RR, and OS and preclinical data suggest synergy between L and T.
Journal ArticleDOI
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
H. A. Burris,Jordi Rodon,Sunil Sharma,Roy S. Herbst,J. Tabernero,J. R. Infante,Antonio P. Silva,David Demanse,Wolfgang Hackl,J. Baselga +9 more
TL;DR: This phase I, multicenter, open-label, single-agent, dose-escalation, study was conducted in pts with histologically confirmed, advanced, unresectable solid tumors and anti-tumor activity of BEZ235 was assessed by CT and PET.
Proceedings ArticleDOI
Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer
J. Baselga,Ian Bradbury,H Eidtmann,S. Di Cosimo,Claudia Aura,E. de Azambuja,Henry L. Gomez,Phuong Dinh,Karine Fauria,V Van Dooren,P Paoletti,A. Goldhirsch,T-W Chang,István Láng,Michael Untch,R. D. Gelber,Martine Piccart-Gebhart +16 more
TL;DR: The NeoALTTO trial is testing the efficacy of lapatinib, trastuzumab or their combination together with paclitaxel when given as neoadjuvant therapy in patients with HER2-positive BC, and evaluating and comparing among the three arms the rate of pCR, defined as the absence of invasive cancer in the breast at the time of surgery.